US$ 700'000 for Swiss Biotech-Company

GeNeuro SA, a Geneva based private biotech company developing therapies for neurology disorders, announces that its clinical program in Schizophrenia led by Professor Marion Leboyer at the University of Creteil in Paris has been awarded more than US$ 700,000 by the Stanley Medical Research Institute. This financing will support the launch of a clinical trial in schizophrenic patients testing a monoclonal antibody targeting a protein, called Env, of endogenous retroviral origin. The Env protein coded by a Human Endogenous Retrovirus type W (HERV-W) gene has been shown to have neurotoxic and inflammatory actions; it is expressed in 40% to 50% of patients with schizophrenia in different populations across the World. Neutralisation of this protein by a specific monoclonal antibody can open the way for a totally new approach in the treatment of psychotic disorders. The first clinical trial with an anti-HERV-Env monoclonal antibody is planned to be launched next year.

About GeNeuro SA
GeNeuro is a privately held biotech company that is focused on developing a pioneering approach for the therapy and diagnosis of diseases associated with human endogenous retrovirus expression with a primary focus on Nervous System diseases. GeNeuro builds a therapeutic product pipeline for disorders with high unmet medical needs, such as multiple sclerosis, schizophrenia, and certain neuropathies. The company’s goal is to optimize the management of the disease, including the treatment, the diagnostic tools and the patient’s follow-up.